Stocks · News reference

Clearmind Medicine Announces DSMB Approval To Advance Phase 1/2 Trial Of CMND-100 Into Parts B And C, Marking First Dosing In Alcohol Use Disorder Patients

Aug 6, 2026, 12:17 PMBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 6, 2026, 12:17 PM
Checked: Aug 6, 2026, 12:17 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 4, 2026, 2:39 PMBenzinga Newsdesk
Clearmind shares are trading lower. The company announced a definitive agreement to acquire a 51% controlling stake in Charging Robotics for an aggregate purchase price of $2.5 million.
CMND
BenzingaSep 4, 2026, 12:59 PMHenry Khederian
Clearmind Medicine Stock Slides Friday: What's Happening?
Clearmind Medicine shares are trading lower Friday as investors weigh the biotech’s move to acquire a majority stake in an EV charging firm.
CMND
BenzingaSep 4, 2026, 11:33 AMBenzinga Newsdesk
Clearmind Medicine Announces $2.5M Deal To Acquire 51% Stake In EV Wireless Charging Firm Charging Robotics, Plus $1.5M Loan At 4%; Expects Close Week Of September 7
CMND
BenzingaSep 1, 2026, 11:38 AMBenzinga News-desk
Clearmind Medicine Initiates Phase lla, Double-Blind, Placebo-Controlled Phase I/IIa Clinical Trial Evaluating CMND-100 For Treatment Of AUD
Clearmind Medicine Inc. (NASDAQ:CMND) (the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric,
CMND